Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience

    October 2023 in “ Journal of Dermatological Treatment ”
    Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, Silvia Mariel Ferrucci, Santo Raffaele Mercuri, Piergiorgio Malagoli, Angelo Valerio Marzano, Mauro Barbareschi, Vittoria Giulia Bianchi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
    TLDR Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
    This study evaluated the effectiveness and safety of baricitinib, a JAK-inhibitor, in 50 patients with severe alopecia areata (AA) over 36 weeks in a real-world setting. Patients received 4 mg of baricitinib daily, and results showed a significant reduction in the Severity of Alopecia Tool (SALT) score, with 54.6% achieving a SALT score of 20 or less by week 36. This response rate was higher than that reported in previous phase-III clinical trials. Baricitinib was well-tolerated, with no serious adverse events leading to discontinuation, although some patients experienced hypercholesterolemia and elevated creatine phosphokinase. The study supports the use of baricitinib for severe AA, aligning with clinical trial data, but suggests further research is needed to confirm long-term effectiveness and safety.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results